|
OmniComm Systems, Inc. Wins A Phase II, Multi-Center International Clinical
Trial For A Major West Coast Biopharmaceutical Company
Electronic Data Capture (EDC) company poised to deliver hosted EDC services for
the first in a series of clinical trials for this industry leader
FT. LAUDERDALE, FL – June 11, 2007 – /MarketWire/ - OmniComm Systems,
Inc. (OTC Bulletin Board: OMCM), one of the fastest growing companies in the EDC
market place, today announced that it has begun working with a multi-billion dollar
West Coast global pharmaceutical company on a Phase II, multi-center study. OmniComm’s
subsidiary in Europe, OmniComm Europe GMBH located in Bonn, Germany will provide
full ASP hosted support and services for the duration of the trial.
“The fact that this key pharmaceutical innovator has chosen OmniComm as its
EDC vendor for this clinical trial is evidence that we are on the right track in
our efforts to deliver superior EDC services and support to the clinical trials
industry,” said Stephen Johnson, Sr. VP of Business Development for OmniComm.
“Our European staff stands ready to deliver first-class customer support and
related trial management services for this industry leader.”
The pharmaceutical company employs the most advanced scientific tools to develop
therapeutics for the treatment of life-threatening diseases. Their goal is to create
innovative therapeutics with enhanced delivery modes, fewer side effects and stronger
efficacy. The company strives to advance the care of patients by developing medicines
that make a significant difference in the treatment of life-threatening diseases.
“Our ultimate goal is to develop a long-term relationship with this
visionary drug development company,” said Cornelis F. Wit, CEO of OmniComm
Systems, Inc. “We feel confident that the ease of use of the TrialMasterTM
EDC solution, coupled with the superior functionality in the product, will exceed
the company’s expectations for this trial and translate into a fruitful relationship
between our two companies.”
About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com)
provides customer-driven Internet solutions to pharmaceutical, biotechnology, research
and medical device organizations that conduct life changing clinical trial research.
OmniComm’s growing base of satisfied customers is a direct result of the company’s
commitment to deliver products and services that ensure ease of use, faster study
build, ease of integration and better performance. OmniComm’s client intuitive
pricing model allows companies that range from small to mid-size to large scale
institutions to safely and efficiently capitalize on their clinical research investments.
OmniComm ranked in the top 150 as one of the fastest revenue growth technology companies
in North America during the last 5 years. In a market overview titled “The
Promise of Next-Gen eClinical Trial Software” by Forrester Research, OmniComm
was given the highest rating among its competitors for industry middleware. OmniComm
Systems Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices
in Bonn, Germany, California, Maryland, New York, North Carolina and Texas.
Safe Harbor Disclaimer
Statements about OmniComm’s future expectations, including without limitation,
future revenues and earnings, plans and objectives for the future operations, future
agreements, future economic performance, operations and all other statements in
this press release other than historical facts are "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933, Section 21E of
the Securities Exchange Act of 1934, and as that term is defined in the Private
Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking
statements be subject to the Safe Harbors created thereby. Since these statements
involve risks and uncertainties, including but not limited to economic competitive,
governmental, contractual and technological factors affecting OmniComm’s operations,
markets and profitability, actual results could differ materially and adversely
from the expected results.
Back
|
